Welcome back to our interview series with Jon Thomas, President and CEO of the California Institute for Regenerative Medicine: CIRM.

How can you ensure your gene therapy research won’t be slowed down by synthesis problems?

Who will be the grand winner of our 2024 Innovation Awards?

Sitting Down With… Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult.

How unified assay protocols and advanced bioinformatics are refining our understanding of mitochondrial dysfunction in complex diseases.

With US courts consistently ruling in favor of the PrEP drug manufacture, the CDC and DHHS have had no choice but to be humble.

What lies ahead for the future of pharma? Dennis van Rooji gives his view.

Trump withdraws the US from the WHO and pharma stakeholders call for changes to price negotiation program

The industry is under pressure to reduce the risks of nitrosamines in both in-development and on-market drug products.

Accelerating the progress of cell and gene therapies with decentralized trials and other innovative approaches.